Journals / Akademik Acil Tıp Dergisi / 2013 / Cilt: 12 - Sayı: 1

Varfarin tedavisine genel bakış ve sorulara cevaplar

Overview of warfarin treatment and answers to questions

Pages
38–42
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our aim is to review knowledge concerning warfarin in routine practice. (JAEM 2013; 12: 38-42)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The increased frequency of referral of patients with warfarin related complications to the emergency unit is worthy of our attention nowadays.
📊
Key Findings & Data:The moscommon reason for this is its role in the prevention of stroke in atrial fibrillation and increased usage of this drug for the high rate of valve surgery.
💡
Conclusion & Impact:Our aim is to review knowledge concerning warfarin in routine practice. (JAEM 2013; 12: 38-42)
🔬Design:Review & Systematic Survey
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

The increased frequency of referral of patients with warfarin related complications to the emergency unit is worthy of our attention nowadays. The moscommon reason for this is its role in the prevention of stroke in atrial fibrillation and increased usage of this drug for the high rate of valve surgery. Bleeding in case of a supratherapeutic effect, its relation with thrombotic complications at subtherapeutic levels and additionally the presence of high risk odrug-drug interaction are important aspects of this drug in routine practice of the cardiologist and emergency physician. Our aim is to review knowledge concerning warfarin in routine practice. (JAEM 2013; 12: 38-42)

Özet

Son zamanlarda acil servise varfarin ilişkili komplikasyonlarla başvuran hasta sayısında artış dikkati çekmektedir. Bunun en önemli nedeni atriyal fibrilasyon hastalarında inmeyi önleyişi ve kapak operasyonlarının artması ile kullanım sıklığında artıştır. Terapötik aralığın üzerine çıkıldığında kanama, subterapötik aralıklarda da trombotik komplikasyonlarla ilişkili olması ve ilaçlarla etkileşiminin sık olması varfarinin kardiyoloji ve acil hekimleri açısından önemini ortaya koymaktadır. Amacımız varfarinle ilgili değerlendirme ve derleme yaparak klinik uygulamada bilinmesi gerekenleri gözden geçirmektir. (JAEM 2013; 12: 38-42)

🔖

Cite This Article

AL, B., ERCAN, S., ALTUNBAŞ, G., DAVUTOĞLU, V. (2022). Varfarin tedavisine genel bakış ve sorulara cevaplar. Akademik Acil Tıp Dergisi, Cilt: 12 - Sayı: 1, 38–42. https://ajindex.com/articles/430302

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD. The first eva- luation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation 2009; 120: 1029-35. [CrossRef] Lane DA, Lip GY. Maintaining therapeutic anticoagulation: the importan- ce of keeping “within range”. Chest 2007; 131: 1277-9. [CrossRef] Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ 2008; 179: 235-44. [CrossRef] Vigué B. Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice. Crit Care 2009; 13: 209. [CrossRef] Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception- cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8. [CrossRef] Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 poly- morphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-9.
  2. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93. [CrossRef] Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol 2011; 57: 612-8. [CrossRef] Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-106. [CrossRef] Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126: 133-6.
  3. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011; 154: 311-24.
  4. Horstkotte D, Piper C, Wiemer M. Optimal Frequency of Patient Monitoring and Intensity of Oral Anticoagulation Therapy in Valvular Heart Disease. J Thromb Thrombolysis 1998; 5: 19-24. [CrossRef] Samsa GP, Matchar DB. Relationship between test frequency and outco- mes of anticoagulation: a literature review and commentary with impli- cations for th